Praxis Precision Medicines Stock Surges 170% on Essential Tremor Drug Success

Praxis Precision Medicines stock rallied over 170% after its experimental essential tremor treatment ulixacaltamide exceeded expectations in two Phase 3 trials, defying earlier pessimism.